Study of CP-675,206 in Refractory Melanoma

• Status: Completed
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

CP-675,206 is a fully human monoclonal antibody (mAb). It binds to the CTLA4 molecule, which is expressed on the surface of activated T lymphocytes. CP-675,206 is thought to stimulate patients' immune systems to attack their tumors. CP-675,206 is not expected to have a direct effect on tumor cells. CP-675,206 been shown to induce durable tumor responses in patients with metastatic melanoma in Phase 1 and Phase 2 clinical studies.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Antibodies, Monoclonal; Tremelimumab

Criteria

Inclusion Criteria:

• Surgically incurable Stage III or IV melanoma

• One prior systemic treatment for metastatic melanoma

• Measurable disease

• Eastern Cooperative Oncology Group (ECOG) PS = 0 or 1

Exclusion Criteria:

• Melanoma of ocular origin

• Received prior vaccine

• Received prior CTLA4-inhibiting agent

• History of, or significant risk for, chronic inflammatory or autoimmune disease

• Potential requirement for systemic corticosteroids